1. Home
  2. NUVL vs CHRD Comparison

NUVL vs CHRD Comparison

Compare NUVL & CHRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.50

Market Cap

9.8B

Sector

Health Care

ML Signal

HOLD

Logo Chord Energy Corporation

CHRD

Chord Energy Corporation

HOLD

Current Price

$116.52

Market Cap

8.2B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
CHRD
Founded
2017
2007
Country
United States
United States
Employees
N/A
676
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
9.8B
8.2B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NUVL
CHRD
Price
$123.50
$116.52
Analyst Decision
Strong Buy
Buy
Analyst Count
16
13
Target Price
$134.75
$149.17
AVG Volume (30 Days)
4.2M
751.6K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
3.56%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$12.56
Revenue Next Year
$1,239.49
N/A
P/E Ratio
N/A
$34.53
Revenue Growth
N/A
N/A
52 Week Low
$71.14
$84.25
52 Week High
$123.69
$151.95

Technical Indicators

Market Signals
Indicator
NUVL
CHRD
Relative Strength Index (RSI) 66.42 29.84
Support Level $97.99 $86.73
Resistance Level $123.62 $127.56
Average True Range (ATR) 0.58 4.11
MACD 0.66 -1.55
Stochastic Oscillator 99.45 3.31

Price Performance

Historical Comparison
NUVL
CHRD

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About CHRD Chord Energy Corporation

Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.

Share on Social Networks: